Tapewire

Nasdaq · USD

CORT

CORCEPT THERAPEUTICS INC

Export transactions ↓
Tapewire entity
2620
SEC CIK
0001088856
Parsed reports
567

Last 12 months

Inside the activity.

2 purchase rows · 107 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025011
Dec 202505
Jan 202601
Feb 202601
Mar 202623
Apr 202601
May 202605
Jun 2026012
Jul 2026026
Aug 2026018
Sep 2026015
Oct 202609

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
June 10, 2025 Filed Jun 13, 2025 00:41 UTC
Guyer WilliamChief Development Officer
Exercise / conversionCommon Stock 20,000 $21.65 $433,000.00
Disclosure

SEC source: 0000950170-25-085755 · ownership.xml · nonDerivative · entry 1

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,487

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 10, 2025 Filed Jun 13, 2025 00:42 UTC GrantStock option (right to buy) · Derivative 15,000 $0.00 Strike: $72.27 $0.00
Disclosure

SEC source: 0000950170-25-085757 · ownership.xml · derivative · entry 4

Swisher Daniel N JR · CIK 0001323113 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-10

F3 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.

Read SEC document
June 10, 2025 Filed Jun 13, 2025 00:42 UTC Exercise / conversionStock option (right to buy) · Derivative 2,200 $0.00 Strike: $14.08 $0.00
Disclosure

SEC source: 0000950170-25-085757 · ownership.xml · derivative · entry 3

Swisher Daniel N JR · CIK 0001323113 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,900

Underlying: Common Stock · 2,200 shares

Expires 2028-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully exercisable.

Read SEC document
June 10, 2025 Filed Jun 13, 2025 00:42 UTC SaleCommon Stock 2,200 $70.61 $155,342.00
Disclosure

SEC source: 0000950170-25-085757 · ownership.xml · nonDerivative · entry 2

Swisher Daniel N JR · CIK 0001323113 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 1, 2024 in effect at the time of this transaction.

Read SEC document
June 10, 2025 Filed Jun 13, 2025 00:42 UTC Exercise / conversionCommon Stock 2,200 $14.08 $30,976.00
Disclosure

SEC source: 0000950170-25-085757 · ownership.xml · nonDerivative · entry 1

Swisher Daniel N JR · CIK 0001323113 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 10, 2025 Filed Jun 13, 2025 00:39 UTC GrantStock option (right to buy) · Derivative 15,000 $0.00 Strike: $72.27 $0.00
Disclosure

SEC source: 0000950170-25-085750 · ownership.xml · derivative · entry 1

MAHONEY DAVID L · CIK 0001224091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-10

F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.

Read SEC document
June 10, 2025 Filed Jun 13, 2025 00:40 UTC GrantStock option (right to buy) · Derivative 15,000 $0.00 Strike: $72.27 $0.00
Disclosure

SEC source: 0000950170-25-085754 · ownership.xml · derivative · entry 1

Alton Gregg H · CIK 0001334682 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-10

F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly vesting date.

Read SEC document
June 10, 2025 Filed Jun 13, 2025 00:08 UTC GrantStock Option (Right To Buy) · Derivative 15,000 $0.00 Strike: $72.27 $0.00
Disclosure

SEC source: 0001225208-25-005922 · doc4.xml · derivative · entry 1

BAKER G LEONARD JR · CIK 0001201715 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-10

F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of June 10, 2025 over a one-year period, subject to the Reporting Person's continued service on each monthly venting date.

Read SEC document
June 03, 2025 Filed Jun 5, 2025 00:34 UTC Tax withholdingCommon Stock 441 $71.68 $31,610.88
Disclosure

SEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 6

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,066

F8 · kind: These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of share upon the vesting of restricted stock units.

F9 · price: The closing price on June 2, 2025 was used to calculate the withholding obligation.

F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 03, 2025 Filed Jun 5, 2025 00:32 UTC
Robb Gary CharlesChief Business Officer
Tax withholdingCommon Stock 651 $71.68 $46,663.68
Disclosure

SEC source: 0000950170-25-081932 · ownership.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,549

F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

F6 · price: The closing price on June 2, 2025 was used to calculate the withholding obligation.

F3 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 03, 2025 Filed Jun 5, 2025 00:32 UTC
Mokari AtabakChief Financial Officer
Tax withholdingCommon Stock 519 $71.68 $37,201.92
Disclosure

SEC source: 0000950170-25-081930 · ownership.xml · nonDerivative · entry 3

Mokari Atabak · CIK 0001678419 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,065

F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

F6 · price: The closing price on June 2, 2025 was used to calculate the withholding obligation.

F3 · balance_after: Includes 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC
BELANOFF JOSEPH KDirector · Chief Executive Officer
SaleCommon Stock 8,408 $85.01 $714,777.53
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 8

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,901,985

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F10 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.00 to $85.31 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC
BELANOFF JOSEPH KDirector · Chief Executive Officer
SaleCommon Stock 12,959 $84.57 $1,095,962.07
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 7

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,910,393

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F9 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.975 to $84.94 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC
BELANOFF JOSEPH KDirector · Chief Executive Officer
SaleCommon Stock 4,631 $83.46 $386,523.17
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 6

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,923,352

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F8 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $82.96 to $83.95 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC
BELANOFF JOSEPH KDirector · Chief Executive Officer
SaleCommon Stock 1,263 $82.26 $103,898.67
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 5

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,927,983

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F7 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $81.935 to $82.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC
BELANOFF JOSEPH KDirector · Chief Executive Officer
SaleCommon Stock 1,820 $81.33 $148,012.41
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 4

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,929,246

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.92 to $81.78 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC
BELANOFF JOSEPH KDirector · Chief Executive Officer
SaleCommon Stock 2,988 $80.30 $239,941.48
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 3

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,931,066

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.90 to $80.8925 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC
BELANOFF JOSEPH KDirector · Chief Executive Officer
SaleCommon Stock 3,050 $79.48 $242,421.02
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 2

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,934,054

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.88 to $79.865 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:41 UTC
BELANOFF JOSEPH KDirector · Chief Executive Officer
SaleCommon Stock 4,881 $78.42 $382,773.39
Disclosure

SEC source: 0000950170-25-081939 · ownership.xml · nonDerivative · entry 1

BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02

Disclosed balance after: 2,937,104

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.84 to $78.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:34 UTC Exercise / conversionStock option (right to buy) · Derivative 5,000 $0.00 Strike: $13.56 $0.00
Disclosure

SEC source: 0000950170-25-081935 · ownership.xml · derivative · entry 7

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,571

Underlying: Common Stock · 5,000 shares

Expires 2030-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Fully exercisable.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:34 UTC GrantCommon Stock 749 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 5

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,507

F7 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:34 UTC GrantCommon Stock 749 $71.68 $53,688.32
Disclosure

SEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 4

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,758

F5 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025.

F6 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:34 UTC SaleCommon Stock 562 $78.65 $44,204.00
Disclosure

SEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 3

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,009

F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $78.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:34 UTC SaleCommon Stock 4,438 $77.97 $346,014.44
Disclosure

SEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 2

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,751

F2 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.55 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:34 UTC Exercise / conversionCommon Stock 5,000 $13.56 $67,800.00
Disclosure

SEC source: 0000950170-25-081935 · ownership.xml · nonDerivative · entry 1

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:32 UTC
Robb Gary CharlesChief Business Officer
GrantCommon Stock 997 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-081932 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,200

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:32 UTC
Robb Gary CharlesChief Business Officer
GrantCommon Stock 997 $71.68 $71,464.96
Disclosure

SEC source: 0000950170-25-081932 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,203

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:33 UTC
Maduck SeanSee Remarks
Exercise / conversionStock option (right to buy) · Derivative 20,000 $0.00 Strike: $5.05 $0.00
Disclosure

SEC source: 0000950170-25-081933 · ownership.xml · derivative · entry 10

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,986

Underlying: Common Stock · 20,000 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Fully exercisable.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:33 UTC
Maduck SeanSee Remarks
SaleCommon Stock 1,811 $80.77 $146,268.86
Disclosure

SEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 7

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,705

F5 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.

F9 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.585 to $81.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:33 UTC
Maduck SeanSee Remarks
SaleCommon Stock 6,246 $79.89 $498,967.33
Disclosure

SEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 6

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,516

F5 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.

F8 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.5725 to $80.535 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:33 UTC
Maduck SeanSee Remarks
SaleCommon Stock 6,191 $78.87 $488,311.41
Disclosure

SEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 5

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,762

F5 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.

F7 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $79.5675 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:33 UTC
Maduck SeanSee Remarks
SaleCommon Stock 5,752 $77.91 $448,138.90
Disclosure

SEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 4

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,953

F5 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.

F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.515 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:33 UTC
Maduck SeanSee Remarks
GrantCommon Stock 20,000 $5.05 $101,000.00
Disclosure

SEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 3

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,705

F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:33 UTC
Maduck SeanSee Remarks
GrantCommon Stock 888 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 2

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,705

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:33 UTC
Maduck SeanSee Remarks
GrantCommon Stock 888 $71.68 $63,651.84
Disclosure

SEC source: 0000950170-25-081933 · ownership.xml · nonDerivative · entry 1

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,817

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:32 UTC
Mokari AtabakChief Financial Officer
GrantCommon Stock 775 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-081930 · ownership.xml · nonDerivative · entry 2

Mokari Atabak · CIK 0001678419 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,584

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 02, 2025 Filed Jun 5, 2025 00:32 UTC
Mokari AtabakChief Financial Officer
GrantCommon Stock 775 $71.68 $55,552.00
Disclosure

SEC source: 0000950170-25-081930 · ownership.xml · nonDerivative · entry 1

Mokari Atabak · CIK 0001678419 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,809

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 29, 2025 Filed Jun 3, 2025 00:57 UTC
Maduck SeanSee Remarks
Exercise / conversionStock option (right to buy) · Derivative 10,000 $0.00 Strike: $3.88 $0.00
Disclosure

SEC source: 0000950170-25-080528 · ownership.xml · derivative · entry 25

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Fully exercisable.

Read SEC document
May 29, 2025 Filed Jun 3, 2025 00:57 UTC
Maduck SeanSee Remarks
OtherCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 23

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 89,693

F2 · kind: Transfer of shares without consideration to the Sean and Molly Maduck Living Trust.

F3 · ownership.nature: Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

Read SEC document
May 29, 2025 Filed Jun 3, 2025 00:57 UTC
Maduck SeanSee Remarks
GiftCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 22

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,929

F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 29, 2025 Filed Jun 3, 2025 00:57 UTC
Maduck SeanSee Remarks
Exercise / conversionCommon Stock 10,000 $3.88 $38,800.00
Disclosure

SEC source: 0000950170-25-080528 · ownership.xml · nonDerivative · entry 21

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,929

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:48 UTC
Robb Gary CharlesChief Business Officer
GiftCommon Stock 360 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-076417 · ownership.xml · nonDerivative · entry 4

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 11,571

F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:48 UTC
Robb Gary CharlesChief Business Officer
GiftCommon Stock 360 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-076417 · ownership.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 11,571

F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:48 UTC
Robb Gary CharlesChief Business Officer
GiftCommon Stock 1,380 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-076417 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,206

F1 · balance_after: Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 20, 2025 Filed May 22, 2025 20:48 UTC
Robb Gary CharlesChief Business Officer
SaleCommon Stock 2,279 $75.85 $172,862.15
Disclosure

SEC source: 0000950170-25-076417 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,586

F1 · balance_after: Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 16, 2025 Filed May 20, 2025 23:35 UTC
Guyer WilliamChief Development Officer
Exercise / conversionStock option (right to buy) · Derivative 32,262 $0.00 Strike: $21.65 $0.00
Disclosure

SEC source: 0000950170-25-075484 · ownership.xml · derivative · entry 3

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 410,000

Underlying: Common Stock · 32,262 shares

Expires 2031-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully exercisable.

Read SEC document
May 16, 2025 Filed May 20, 2025 23:35 UTC
Guyer WilliamChief Development Officer
SaleCommon Stock 32,262 $74.17 $2,393,014.49
Disclosure

SEC source: 0000950170-25-075484 · ownership.xml · nonDerivative · entry 2

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,487

F1 · kind: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.94 to $74.66 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document
May 16, 2025 Filed May 20, 2025 23:35 UTC
Guyer WilliamChief Development Officer
Exercise / conversionCommon Stock 32,262 $21.65 $698,472.30
Disclosure

SEC source: 0000950170-25-075484 · ownership.xml · nonDerivative · entry 1

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,749

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 16, 2025 Filed May 20, 2025 23:13 UTC Exercise / conversionStock option (right to buy) · Derivative 30,000 $0.00 Strike: $6.55 $0.00
Disclosure

SEC source: 0000950170-25-075470 · ownership.xml · derivative · entry 7

MAHONEY DAVID L · CIK 0001224091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2025-06-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully exercisable.

Read SEC document
May 16, 2025 Filed May 20, 2025 23:13 UTC SaleCommon Stock 3,523 $74.65 $263,000.76
Disclosure

SEC source: 0000950170-25-075470 · ownership.xml · nonDerivative · entry 4

MAHONEY DAVID L · CIK 0001224091 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.54 to $74.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.